This inventor holds 2 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent. Top assignee: Immunitybio, Inc.. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Jason Isaacson: Innovator in Mononuclear Cell Derived NK Cells
Introduction
Jason Isaacson is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of immunotherapy, particularly in the development of novel methods for preparing natural killer (NK) cells from mononuclear cells.
Latest Patents
Jason holds two patents related to his innovative work. His latest patents focus on the preparation of cord blood or peripheral blood NK cells from whole blood mononuclear cells. These methods eliminate the need to isolate CD34+ hematopoietic stem cells or NK cells, as well as the requirement for a feeder layer. The processes utilize an enrichment method involving antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Furthermore, these methods are designed to be adaptable into a fully automated production process, referred to as "GMP in a box."
Career Highlights
Jason is currently associated with ImmunityBio, Inc., where he continues to advance his research and development efforts. His work is pivotal in enhancing the efficacy of immunotherapies, which have the potential to revolutionize cancer treatment.
Collaborations
Some of Jason's notable coworkers include Rohit Duggal and Ranjeet Sinha, who collaborate with him in various research initiatives.
Conclusion
Jason Isaacson's innovative work in the field of NK cell preparation showcases his commitment to advancing medical science. His contributions are paving the way for new therapeutic approaches in immunotherapy.